GenMark Diagnostics

Health diagnostics medical devices testing

GenMark Diagnostics is a provider of automated, multiplex molecular diagnostic testing systems. The Company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration -cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. GenMark also offers a Hepatitis C genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only.

Revenue(FY, 2017)

$52.5 M

Market capitalization(2018-04-18)

$329.6 M

Type

Public

Carlsbad, US

Founded

2010

Size (employees)

308 (est)

Website

genmarkdx.com

GenMark Diagnostics was founded in 2010 and is headquartered in Carlsbad, US

Report incorrect company information

Key People/Management at GenMark Diagnostics

Hany Massarany

President and Chief Executive Officer

Scott Mendel

Chief Financial Officer

Jon Kayyem

Founder and Senior Vice President, Research and Development

Michael Gleeson

Senior Vice President, North American Commercial Operations

James McNally

Senior Vice President, Marketing and Business Development

Brian Mitchell

Senior Vice President, Operations

Report incorrect company information

GenMark Diagnostics Office Locations

GenMark Diagnostics has offices in Manchester, Bristol, Buffalo, Albany and in 32 other locations

Carlsbad, US (HQ)

5964 La Pl Ct

Zug, CH

6 General-Guisan-Strasse

Show all (36)

Report incorrect company information

GenMark Diagnostics Financials and Metrics

GenMark Diagnostics Financials

GenMark Diagnostics's revenue was reported to be $52.52 m in FY, 2017

Summary

USD
Revenue (FY, 2017)	52.5 m
Gross profit (FY, 2017)	20 m
Gross profit margin (FY, 2017), %	38.1%
Net income (FY, 2017)	(61.9 m)
EBIT (FY, 2017)	(59.5 m)
Market capitalization (18-Apr-2018)	329.6 m
Cash (31-Dec-2017)	26.8 m
EV	330.9 m

GenMark Diagnostics's current market capitalization is $329.6 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	27.4 m	30.6 m	39.4 m	49.3 m	52.5 m
Revenue growth, %		12%	29%	25%
Cost of goods sold			15.3 m	19.7 m	32.5 m
Gross profit			24.1 m	29.6 m	20 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Revenue	4.6 m	7.9 m	6.6 m	6.3 m	10.1 m	7.6 m	8.5 m	11.1 b	12.5 m	10.8 m	12.5 b	12.4 m
Cost of goods sold	4.1 m	3.7 m	3.2 m	2.7 m	4 m	3.3 m	3.4 m	4.4 b	4.7 m	4.4 m	6.4 b	7.5 m
Gross profit	499 k	4.2 m	3.4 m	3.6 m	6.1 m	4.4 m	5.1 m	6.7 b	7.8 m	6.5 m	6.2 b	4.9 m
Gross profit Margin, %	11%	53%	51%	57%	61%	57%	60%	60%	62%	60%	49%	40%

show all

Balance Sheet

Annual

usd	Y, 2009	Y, 2010	Y, 2011	Y, 2012	Y, 2013	Y, 2014	Y, 2015	FY, 2016	FY, 2017
Cash	16.5 m	51.3 m	25.3 m	51.3 m	35.7 m	36.9 m	35.4 m	16 m	26.8 m
Accounts Receivable
Inventories					2.1 m	2.1 m	3.1 m	3.1 m	10.9 m
Current Assets					111.1 m	78.1 m	56 m	58.4 m	95.4 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017
Cash	63.3 m	27.9 m	26.8 m	25.7 m	36.9 m	32.1 m	34.2 m	27.9 m	29.6 m	19.3 m	13.2 m	88.4 m
Inventories	2 m	1.8 m	1.2 m	1.5 m	2.1 m	2 m	2.7 m	2.4 m	2.6 m	4.2 m	9 m	7.1 m
Current Assets	117.5 m	102.6 m	93.8 m	84.7 m	78.3 m	69.1 m	62.1 m	46.5 m	46.8 m	64.7 m	42.1 m	122.2 m
PP&E	7.9 m	9.6 m	9.9 m	10.2 m	11.4 m	11.8 m	11.6 m	11.7 m	12.7 m	17.3 m	18.5 m	19.8 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(33.6 m)	(38.3 m)	(42.2 m)	(50.6 m)	(61.9 m)
Depreciation and Amortization	2.5 m	2.7 m	3.4 m	3.9 m	5.3 m
Inventories	(1.3 m)	(229 k)	(3.5 m)	(3.5 m)	(10.5 m)
Accounts Payable	1.3 m	85 k	4.1 m	4.1 m	2.6 m